optima-logo.png
Opthea To Present at H.C. Wainwright BIOCONNECT Virtual Conference
04 janv. 2022 06h18 HE | Opthea Limited
MELBOURNE, Australia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive...
optima-logo.png
Opthea Appoints Chief Commercial Officer to Lead Commercialization of OPT-302 for Wet AMD
03 janv. 2022 06h00 HE | Opthea Limited
MELBOURNE, Australia, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
optima-logo.png
Opthea Granted Chinese Patent Covering OPT-302
26 oct. 2021 06h00 HE | Opthea Limited
MELBOURNE, Australia, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
optima-logo.png
Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST Phase 3 Trials in Wet AMD
19 oct. 2021 06h00 HE | Opthea Limited
MELBOURNE, Australia, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
optima-logo.png
Opthea Opens Patient Recruitment in Europe for Pivotal Phase 3 ShORe and COAST Wet AMD Trials of OPT-302
04 oct. 2021 07h00 HE | Opthea Limited
MELBOURNE, Australia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
optima-logo.png
Opthea To Present at September Investor Conferences
02 sept. 2021 07h00 HE | Opthea Limited
MELBOURNE, Australia, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive...
optima-logo.png
Opthea Reports Fiscal Year 2021 Financial Results and Corporate Highlights
30 août 2021 07h00 HE | Opthea Limited
Treated First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet Age-Related Macular Degeneration (AMD) OPT-302 Granted FDA Fast Track Designation for Wet AMD Received FDA Waiver for Pediatric...
optima-logo.png
Opthea To Present at the H.C. Wainwright Ophthalmology Virtual Conference
10 août 2021 07h00 HE | Opthea Limited
MELBOURNE, Australia, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive...
optima-logo.png
Opthea Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada
09 août 2021 07h00 HE | Opthea Limited
MELBOURNE, Australia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
optima-logo.png
Opthea’s OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration
06 juil. 2021 07h00 HE | Opthea Limited
MELBOURNE, Australia, July 06, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...